Unknown

Dataset Information

0

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.


ABSTRACT: Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type TP53, and thus, therapies targeting the p53 pathway would benefit most patients. To discover targets specific for TP53 wild-type Ewing sarcoma, we used a genome-scale CRISPR-Cas9 screening approach and identified and validated MDM2, MDM4, USP7, and PPM1D as druggable dependencies. The stapled peptide inhibitor of MDM2 and MDM4, ATSP-7041, showed anti-tumor efficacy in vitro and in multiple mouse models. The USP7 inhibitor, P5091, and the Wip1/PPM1D inhibitor, GSK2830371, decreased the viability of Ewing sarcoma cells. The combination of ATSP-7041 with P5091, GSK2830371, and chemotherapeutic agents showed synergistic action on the p53 pathway. The effects of the inhibitors, including the specific USP7 inhibitor XL-188, were rescued by concurrent TP53 knockout, highlighting the essentiality of intact p53 for the observed cytotoxic activities.

SUBMITTER: Stolte B 

PROVIDER: S-EPMC6080915 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7840125 | biostudies-literature
| S-EPMC9225990 | biostudies-literature
| S-EPMC7818247 | biostudies-literature
| S-EPMC8345183 | biostudies-literature
| S-EPMC5159885 | biostudies-literature
| S-EPMC10474113 | biostudies-literature
| S-EPMC8368014 | biostudies-literature
| S-EPMC6768851 | biostudies-literature
| S-EPMC9849354 | biostudies-literature
| S-EPMC6636827 | biostudies-literature